Trevi Therapeutics Inc. (NASDAQ: TRVI) announced that data from its Phase 2a RIVER trial of nalbuphine ER for refractory chronic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE